View:

Download DOC

Download PDF

Download XLS

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)*

KalVista Pharmaceuticals, Inc. (Name of Issuer)

Common Stock, $0.001 par value per share (Title of Class of Securities)

(CUSIP Number)

Jennifer Martin 1700 Seventh Ave, Suite 1120, Seattle, WA, 98101 (206) 451-8040 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

05/19/2026 (Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Frazier Life Sciences Public Fund, L.P.
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) WC
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 1,249,165.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 1,249,165.00
11	Aggregate amount beneficially owned by each reporting person 1,249,165.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 2.3 %
14	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person FHMLSP, L.P.
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 1,249,165.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 1,249,165.00
11	Aggregate amount beneficially owned by each reporting person 1,249,165.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 2.3 %
14	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person FHMLSP, L.L.C.
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 1,249,165.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 1,249,165.00
11	Aggregate amount beneficially owned by each reporting person 1,249,165.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 2.3 %
14	Type of Reporting Person (See Instructions) OO

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Frazier Life Sciences X, L.P.
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) WC
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 427,983.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 427,983.00
11	Aggregate amount beneficially owned by each reporting person 427,983.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 0.8 %
14	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person FHMLS X, L.P.
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 427,983.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 427,983.00
11	Aggregate amount beneficially owned by each reporting person 427,983.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 0.8 %
14	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person FHMLS X, L.L.C.
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 427,983.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 427,983.00
11	Aggregate amount beneficially owned by each reporting person 427,983.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 0.8 %
14	Type of Reporting Person (See Instructions) OO

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Frazier Life Sciences XI, L.P.
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) WC
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 145,592.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 145,592.00
11	Aggregate amount beneficially owned by each reporting person 145,592.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 0.3 %
14	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person FHMLS XI, L.P.
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 145,592.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 145,592.00
11	Aggregate amount beneficially owned by each reporting person 145,592.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 0.3 %
14	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person FHMLS XI, L.L.C.
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 145,592.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 145,592.00
11	Aggregate amount beneficially owned by each reporting person 145,592.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 0.8 %
14	Type of Reporting Person (See Instructions) OO

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Frazier Life Sciences XII, L.P.
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) WC
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 6,563.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 6,563.00
11	Aggregate amount beneficially owned by each reporting person 6,563.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 0.0 %
14	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person FHMLS XII, L.P.
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 6,563.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 6,563.00
11	Aggregate amount beneficially owned by each reporting person 6,563.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 0.0 %
14	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person FHMLS XII, L.L.C.
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 6,563.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 6,563.00
11	Aggregate amount beneficially owned by each reporting person 6,563.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 0.0 %
14	Type of Reporting Person (See Instructions) OO

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person James N. Topper
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 427,983.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 427,983.00
11	Aggregate amount beneficially owned by each reporting person 427,983.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 0.8 %
14	Type of Reporting Person (See Instructions) IN

Comment for Type of Reporting Person:

The shares listed in rows 8, 10 and 11 represent shares of Common Stock held directly by Frazier Life Sciences X, L.P. The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Patrick J. Heron
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 427,983.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 427,983.00
11	Aggregate amount beneficially owned by each reporting person 427,983.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 0.8 %
14	Type of Reporting Person (See Instructions) IN

Comment for Type of Reporting Person:

The shares listed in rows 8, 10 and 11 represent shares of Common Stock held directly by Frazier Life Sciences X, L.P. The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, $0.001 par value per share
(b)	Name of Issuer: KalVista Pharmaceuticals, Inc.
(c)	Address of Issuer's Principal Executive Offices: 200 Crossing Boulevard, Framingham, MASSACHUSETTS , 01702.
Item 1 Comment: This Amendment No. 8 ("Amendment No. 8") to Schedule 13D amends the statement on Schedule 13D filed on December 30, 2021 (the "Original Schedule 13D") as amended on January 26, 2022, December 30, 2022, December 14, 2023, February 22, 2024, November 7, 2024, August 20, 2025 and November 4, 2025 (the "Prior Amendments", and together with the Original Schedule 13D and this Amendment No. 8, the "Schedule 13D"). Except as otherwise specified in Amendment No. 8, all items in the Original Schedule 13D, as amended by the Prior Amendments, are unchanged. All capitalized terms used in this Amendment No. 8 and not otherwise defined herein have the meanings ascribed to such terms in the Original Schedule 13D, as amended by the Prior Amendments.
Item 2.	Identity and Background
(a)	Item 2(a) is hereby amended and restated in its entirety to read as follows: The entities and persons filing this statement (collectively, the "Reporting Persons") are: Frazier Life Sciences Public Fund, L.P. ("FLSPF") FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences X, L.P. ("FLS X") FHMLS X, L.P. FHMLS X, L.L.C. Frazier Life Sciences XI, L.P. ("FLS XI") FHMLS XI, L.P. FHMLS XI, L.L.C. Frazier Life Sciences XII, L.P. ("FLS XII") FHMLS XII, L.P. FHMLS XII, L.L.C. James N. Topper ("Topper") Patrick J. Heron ("Heron" and together with Topper, the "Members")
(b)	Item 2(b) is hereby amended and restated in its entirety to read as follows: The address of the principal place of business for each of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 1001 Page Mill Rd, Building 4, Suite 200B Palo Alto, CA 94304
(c)	Item 2(c) is hereby amended and restated in its entirety to read as follows: FLSPF is a venture capital fund concentrating in life sciences and related fields. The sole business of FHMLSP, L.P. is to serve as general partner of FLSPF. The sole business of FHMLSP, L.L.C. is to serve as general partner of FHMLSP, L.P. FLS X is a venture capital fund concentrating in life sciences and related fields. The sole business of FHMLS X, L.P. is to serve as general partner of FLS IX. The sole business of FHMLS X, L.L.C. is to serve as general partner of FHMLS X, L.P. FLS XI is a venture capital fund concentrating in life sciences and related fields. The sole business of FHMLS XI, L.P. is to serve as general partner of FLS XI. The sole business of FHMLS XI, L.L.C. is to serve as general partner of FHMLS XI, L.P. FLS XII is a venture capital fund concentrating in life sciences and related fields. The sole business of FHMLS XII, L.P. is to serve as general partner of FLS XII. The sole business of FHMLS XII, L.L.C. is to serve as general partner of FHMLS XII, L.P. The principal business of the Members is to manage FLSPF, FHMLSP, L.P., FHMLSP, L.L.C., FLS X, FHMLS X, L.P., FHMLS X, L.L.C., FLS XI, FHMLS XI, L.P., FHMLS XI, L.L.C., FLS XII, FHMLS XII, L.P., FHMLS XII, L.L.C. and a number of affiliated partnerships with similar businesses.
(f)	Item 2(f) is hereby amended and restated in its entirety to read as follows: Entities: FLSPF - Delaware, U.S.A. FHMLSP, L.P. - Delaware, U.S.A. FHMLSP, L.L.C. - Delaware, U.S.A. FLS X - Delaware, U.S.A. FHMLS X, L.P. - Delaware, U.S.A. FHMLS X, L.L.C. - Delaware, U.S.A. FLS XI - Delaware, U.S.A. FHMLS XI, L.P. - Delaware, U.S.A. FHMLS XI, L.L.C. - Delaware, U.S.A. FLS XII - Delaware, U.S.A. FHMLS XII, L.P. - Delaware, U.S.A. FHMLS XII, L.L.C. - Delaware, U.S.A. Individuals: Topper - United States Citizen Heron - United States Citizen
Item 3.	Source and Amount of Funds or Other Consideration
	Item 3 of the Schedule 13D is hereby amended to incorporate Item 5(c) hereof and to replace the last paragraph with the following: The working capital of FLSPF, FLS X, FLS XI and FLS XII was the source of the funds for the purchase of the FLSPF Shares, the FLS X Shares, the FLS XI Shares and the FLS XII Shares. No part of the purchase price of the FLSPF Shares, the FLS X Shares, the FLS XI Shares or the FLS XII Shares was represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting the FLSPF Shares, the FLS X Shares, the FLS XI Shares or the FLS XII Shares.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5(a) is hereby amended and restated in its entirety to read as follows: The information contained in Rows 7, 8, 9, 10, 11, and 13 of each Reporting Person's cover page to this Schedule 13D (including the footnotes thereto) is incorporated by reference into this Item 5. FLSPF directly holds 1,249,165 shares of the Issuer's Common Stock (the "FLSPF Shares"). FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF. FLS X directly holds 427,983 shares of the Issuer's Common Stock (the "FLS X Shares"). FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the FLS X Shares. FLS XI directly holds 145,592 shares of this Issuer's Common Stock (the "FLS XI Shares"). FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI. FLS XII directly holds 6,563 shares of this Issuer's Common Stock (the "FLS XII Shares"). FHMLS XII, L.P. is the general partner of FLS XII and the general partner of FHMLS XII, L.P. is FHMLS XII, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XII. Except as specifically stated herein, the filing of this Schedule 13D shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Schedule 13D or a member of a "group" with any other person.
(c)	Except as set forth on Exhibit 10.1 of this Schedule 13D, none of the Reporting Persons has effected any transactions relating to the Ordinary Shares during the past 60 days.
(e)	May 19, 2026
Item 7.	Material to be Filed as Exhibits.
	Exhibit 10.1 Transactions Relating to the Common Stock of the Issuer During the Past Sixty (60) Days Exhibit 99.1 Joint Filing Agreement

SIGNATURE
	After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Frazier Life Sciences Public Fund, L.P.

Signature: /s/ Jennifer Martin Name/Title: By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P. Date: 05/21/2026

FHMLSP, L.P.

Signature: /s/ Jennifer Martin Name/Title: By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P. Date: 05/21/2026

FHMLSP, L.L.C.

Signature: /s/ Jennifer Martin Name/Title: By Jennifer Martin, CFO of FHMLSP, L.L.C. Date: 05/21/2026

Frazier Life Sciences X, L.P.

Signature: /s/ Jennifer Martin Name/Title: By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P. Date: 05/21/2026

FHMLS X, L.P.

Signature: /s/ Jennifer Martin Name/Title: By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P. Date: 05/21/2026

FHMLS X, L.L.C.

Signature: /s/ Jennifer Martin Name/Title: By Jennifer Martin, CFO of FHMLS X, L.L.C. Date: 05/21/2026

Frazier Life Sciences XI, L.P.

Signature: /s/ Jennifer Martin Name/Title: By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P. Date: 05/21/2026

FHMLS XI, L.P.

Signature: /s/ Jennifer Martin Name/Title: By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P. Date: 05/21/2026

FHMLS XI, L.L.C.

Signature: /s/ Jennifer Martin Name/Title: By Jennifer Martin, CFO of FHMLS XI, L.L.C. Date: 05/21/2026

Frazier Life Sciences XII, L.P.

Signature: /s/ Jennifer Martin Name/Title: By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P. Date: 05/21/2026

FHMLS XII, L.P.

Signature: /s/ Jennifer Martin Name/Title: By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P. Date: 05/21/2026

FHMLS XII, L.L.C.

Signature: /s/ Jennifer Martin Name/Title: By Jennifer Martin, CFO of FHMLS XII, L.L.C. Date: 05/21/2026

James N. Topper

Signature: /s/ Jennifer Martin Name/Title: By Jennifer Martin, Attorney-in-Fact for Patrick J. Heron, pursuant to Power of Attorney Date: 05/21/2026

Patrick J. Heron

Signature: /s/ Jennifer Martin Name/Title: By Jennifer Martin, Attorney-in-Fact for Patrick J. Heron, pursuant to Power of Attorney Date: 05/21/2026

EXHIBIT 10.1

Transactions Relating to the Common Stock of the Issuer During the Past Sixty (60) Days

The following table sets forth all transactions relating to the Common Stock of the Issuer that were effected during the past sixty (60) days by the applicable Reporting Person.

(1)

These shares were sold in multiple transactions at prices ranging from $26.76 to $26.785, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

(2)

These shares were sold in multiple transactions at prices ranging from $26.77 to $26.825, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

EXHIBIT 99.1

JOINT FILING AGREEMENT

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Shares of Common Stock of KalVista Pharmaceuticals, Inc.

Date:  May 21, 2026

FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.

By: FHMLSP, L.P., its General Partner

By: FHMLSP, L.L.C., its General Partner

By: /s/ Jennifer Martin

Jennifer Martin, Chief Financial Officer

Date:  May 21, 2026

FHMLSP, L.P.

By: FHMLSP, L.L.C., its General Partner

By: /s/ Jennifer Martin

Jennifer Martin, Chief Financial Officer

Date:  May 21, 2026

FHMLSP, L.L.C.

By: /s/ Jennifer Martin

Jennifer Martin, Chief Financial Officer

Date:  May 21, 2026

FRAZIER LIFE SCIENCES X, L.P.

By: FHMLS X, L.P., its General Partner

By: FHMLS X, L.L.C., its General Partner

By: /s/ Jennifer Martin

Jennifer Martin, Chief Financial Officer

Date:  May 21, 2026

FHMLS X, L.P.

By: FHMLS X, L.L.C., its General Partner

By: /s/ Jennifer Martin

Jennifer Martin, Chief Financial Officer

Date:  May 21, 2026

FHMLS X, L.L.C.

By: /s/ Jennifer Martin

Jennifer Martin, Chief Financial Officer

Date:  May 21, 2026

FRAZIER LIFE SCIENCES XI, L.P.

By: FHMLS XI, L.P., its General Partner

By: FHMLS XI, L.L.C., its General Partner

By: /s/ Jennifer Martin

Jennifer Martin, Chief Financial Officer

Date:  May 21, 2026

FHMLS XI, L.P.

By: FHMLS XI, L.L.C., its General Partner

By: /s/ Jennifer Martin

Jennifer Martin, Chief Financial Officer

Date:  May 21, 2026

FHMLS XI, L.L.C.

By: /s/ Jennifer Martin

Jennifer Martin, Chief Financial Officer

Date:  May 21, 2026

FRAZIER LIFE SCIENCES XII, L.P.

By: FHMLS XII, L.P., its General Partner

By: FHMLS XII, L.L.C., its General Partner

By: /s/ Jennifer Martin

Jennifer Martin, Chief Financial Officer

Date:  May 21, 2026

FHMLS XII, L.P.

By: FHMLS XII, L.L.C., its General Partner

By: /s/ Jennifer Martin

Jennifer Martin, Chief Financial Officer

Date:  May 21, 2026

FHMLS XII, L.L.C.

By: /s/ Jennifer Martin

Jennifer Martin, Chief Financial Officer

Date:  May 21, 2026

By: *

James N. Topper

Date:  May 21, 2026

By: *

Patrick J. Heron

Date:  May 21, 2026

By: /s/ Jennifer Martin

Jennifer Martin, as Attorney-in-Fact

* This Joint Filing Agreement was executed by Jennifer Martin on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on January 27, 2026.